SCHEMBL3884103

SCHEMBL3884103

CCCCCCCCCCC(CO)NC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 1/20 0.47
GPR84 Q9NQS5 7/20 0.47
FFAR1 O14842 2/20 0.47
LMNA P02545 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.46
LCK P06239 1/20 0.46
PPARD Q03181 1/20 0.46
ZDHHC20 Q5W0Z9 1/20 0.46
ZDHHC2 Q9UIJ5 1/20 0.46
ASAH1 Q13510 1/20 0.45
FFAR4 Q5NUL3 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
PLA2G10 O15496 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7549777 1.00 PLA2G2C (0.47) PLA2G2CGPR84FFAR1LMNAMEN1
SCHEMBL3888142 1.00 PLA2G2C (0.47) PLA2G2CGPR84FFAR1LMNAMEN1
SCHEMBL11050261 1.00 PLA2G2C (0.47) PLA2G2CGPR84FFAR1LMNAMEN1
SCHEMBL7639204 1.00 PLA2G2C (0.47) PLA2G2CGPR84FFAR1LMNAMEN1
SCHEMBL4820666 0.92 PLA2G2C (0.46) PLA2G2CMEN1KMT2AASAH1PLA2G10
SCHEMBL16762206 0.92 PLA2G2C (0.46) PLA2G2CMEN1KMT2AASAH1PLA2G10
SCHEMBL4820679 0.92 PLA2G2C (0.46) PLA2G2CMEN1KMT2AASAH1PLA2G10
SCHEMBL20459227 0.90 PLA2G2C (0.56) PLA2G2CGPR84FFAR1MAPTLCK
SCHEMBL20459159 0.90 PLA2G2C (0.56) PLA2G2CGPR84FFAR1MAPTLCK
SCHEMBL5012513 0.90 PLA2G2C (0.56) PLA2G2CGPR84FFAR1MAPTLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565179-B1 COMPOSITION COMPRISING A CARBAMIC ACID DERIVATIVE, ITS USE AS COSMETIC AND MEDICINE EXPANSCIENCE LAB (FR) 2009-01-14 EP claimed
US-8653117-B2 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof LABORATOIRES EXPANSCIENCE (FR) 2014-02-18 US disclosed
US-8304453-B2 Composition comprising at least one alkanolamide to inhibit migration of langerhans cells and uses therof LABORATOIRES EXPANSCIENCE (FR) 2012-11-06 US disclosed
US-8236836-B2 Antiinflammatory agents, soothing agents, enzyme inhibitors, chelate compounds or alkanolamides using oxazoline derivatives LABORATOIRES EXPANSCIENCE (FR) 2012-08-07 US disclosed
CN-1617704-B Composition comprising at least one oxazolin for inhibiting langerhans cell migration, and uses thereof EXPANSCIENCE LAB 2011-10-05 CN disclosed
CN-1617703-B Composition comprising at least one alkanolamide for inhibiting Langerhans cell migration and uses thereof EXPANSCIENCE LAB 2010-12-01 CN disclosed
US-20090137453-A1 COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE TO INHIBIT MIGRATION OF LANGERHANS CELLS, AND USES THEREOF MSIKA PHILIPPE 2009-05-28 US disclosed
US-20060194881-A1 Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof MSIKA PHILIPPE 2006-08-31 US disclosed
CN-1617703-A Composition comprising at least one alkanolamide for inhibiting Langerhans cell migration and uses thereof EXPANSCIENCE LAB (FR) 2005-05-18 CN disclosed
CN-1617704-A Composition comprising at least one oxazolin for inhibiting langerhans cell migration, and uses thereof EXPANSCIENCE LAB (FR) 2005-05-18 CN disclosed
US-20050075380-A1 Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof LABORATOIRES EXPANSCIENCE (FR) 2005-04-07 US disclosed
US-20050075397-A1 Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof LABORATOIRES EXPANSCIENCE (FR) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075397-A1 Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof ARG1, CPA3, MIF PLA2G2C 2686/4885GPR84 534/4885FFAR1 1100/4885
US-20090137453-A1 COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE TO INHIBIT MIGRATION OF LANGERHANS CELLS, AND USES THEREOF ARG1, MIF, ZAP70 PLA2G2C 2760/4885GPR84 654/4885FFAR1 1409/4885
US-20050075380-A1 Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof MIF, CUTA, ARG1 PLA2G2C 1696/4885GPR84 958/4885FFAR1 1205/4885
US-20060194881-A1 Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof TPSG1, CPA3, CTSF PLA2G2C 3839/4885GPR84 303/4885FFAR1 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.